BioNTech’s (BNTX) “Buy” Rating Reiterated at Deutsche Bank Aktiengesellschaft

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday,MarketScreener reports.

Several other brokerages also recently commented on BNTX. UBS Group raised shares of BioNTech to a “hold” rating in a research note on Thursday, December 4th. Citigroup decreased their target price on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Jefferies Financial Group cut their price target on BioNTech from $151.00 to $138.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Leerink Partners cut BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target for the company. in a research note on Monday, February 2nd. Thirteen equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $133.73.

BioNTech Price Performance

Shares of BNTX stock opened at $91.73 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49. The stock’s fifty day simple moving average is $106.30 and its 200 day simple moving average is $102.46. BioNTech has a one year low of $79.52 and a one year high of $124.00. The firm has a market cap of $22.01 billion, a price-to-earnings ratio of -17.48 and a beta of 1.51.

Hedge Funds Weigh In On BioNTech

Large investors have recently bought and sold shares of the stock. Larson Financial Group LLC increased its stake in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the last quarter. EFG International AG bought a new position in BioNTech during the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd increased its position in BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares during the last quarter. Financial Consulate Inc. bought a new position in BioNTech in the third quarter valued at about $36,000. Finally, Huntington National Bank increased its position in shares of BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.